Precision Medicine Online

1 week ago | precisionmedicineonline.com | Alison Kanski

NEW YORK – Amgen reported growth across its precision oncology portfolio in the first quarter of the year, led by the bispecific T-cell engager Blincyto (blinatumomab), and talked up two of its investigational oncology candidates for FGFR- and KRAS-mutant cancers. The firm's FGFRb-targeted monoclonal antibody, bemarituzumab, is undergoing testing in several studies involving patients with gastric cancers that overexpress FGFR2b.

1 week ago | precisionmedicineonline.com | Forest Ray

NEW YORK – Donor-derived cell-free DNA (dd-cfDNA)-based liquid biopsies are beginning to change clinical practice in the heart transplant space and may be poised for stronger guideline recommendations in the near future.

1 week ago | precisionmedicineonline.com | Alison Kanski

CHICAGO – After Genentech's anti-TIGIT immunotherapy combination failed to meet its primary endpoint in a late-stage study, experts at the American Association for Cancer Research's annual meeting considered the future of this drug class in non-small cell lung cancer. Researchers reported the full data readout from the Phase III SKYSCRAPER-01 trial of tiragolumab plus Genentech's PD-L1 immunotherapy Tecentriq (atezolizumab) in first-line PD-L1-high advanced NSCLC at the meeting on Monday.

1 week ago | precisionmedicineonline.com | Molika Ashford

NEW YORK – Veracyte is in the midst of an effort to prove out the minimal residual disease technology adopted with its acquisition of C2i Genomics last year, and said last week that new data presented at the European Association of Urology Congress have left it confident that it will be able to launch the test for bladder cancer monitoring in the first half of 2026. The C2i approach is tumor informed, akin to tests developed by firms like Natera, Inivata (part of NeoGenomics), and others.

2 weeks ago | precisionmedicineonline.com | Julia Karow

NEW YORK – Promega said on Tuesday that its ProDx MSI Detection Kit has received an innovative medical device registration certificate from China's National Medical Products Administration (NMPA).